Therapeutic Strategies for Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a clinically relevant term referring to breast carcinomas that do not express the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor type 2 and became operational after human epidermal growth factor receptor type 2 testing was introduced. This is a challenging disease to treat because of the absence of a specific target. but these tumors are sensitive to chemotherapy. An improved Understanding of the biology of TNBC has led to evaluation Of DNA-damaging chemotherapy drugs. specifically, platinum compounds, and several targeted agents, including poly(ADP-ribose) polymerase inhibitors, epidermal growth factor receptor inhibitors, angiogenesis inhibitors, microtubule inhibitors. Src inhibitors, checkpoint kinase I inhibitors. mammalian tar et of raparmycin inhibitors, androgen receptor blocker. tumor necrosis factor-related apoptosis-including ligand receptor agonists, and transforming growth factor-beta antagonists, that may lead to improved clinical outcomes. Ongoing clinical trials will further define the optimal chemotherapy regimen and most effective targeted therapeutic strategy for TNBC.